



Eligibility Criteria

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucaium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough

Protocol number: NOC110-C-202

Protocol version: 2.0

Date of Protocol: 18 July 2024

